ArticleScientific reports2015
Biological determinants of bladder cancer gene expression subtypes.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review.Investigative and clinical urology · 2023Pooled it
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.EBioMedicine · 2016Pooled it
- [Development of a 36-gene signature for predicting recurrence in non-muscle-invasive bladder cancer and validation in a Chinese cohort].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer.Cell reports. Medicine · 2025Article
- Development of a novel immunocompetent murine tumor model for urothelial carcinoma using in vivo electroporation.Scientific reports · 2024Article
- Molecular Landscape of Bladder Cancer: Key Genes, Transcription Factors, and Drug Interactions.International journal of molecular sciences · 2024Article
- Integration of CD4Cancer science · 2024Article
- Article
- Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma.Annals of diagnostic pathology · 2023Article
- Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression.Cancers · 2022Article
- Article
- Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients.International journal of molecular sciences · 2022Article
- Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Article
- Review
- REVIEW OF THE BLADDER CANCER MOLECULAR CLASSIFICATION PROPOSED: A NEW ERA - NEW TAXONOMY.Acta clinica Croatica · 2022Review
- Comparison of RNAscope and immunohistochemistry for evaluation of the UPK2 status in urothelial carcinoma tissues.Diagnostic pathology · 2022Article
- Article
- Multi-resolution characterization of molecular taxonomies in bulk and single-cell transcriptomics data.Nucleic acids research · 2021Article
- Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.Journal of cellular and molecular medicine · 2021Article
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular stratification of tumors by gene expression profiling has been applied to a large number of human malignancies and holds great promise for personalized treatment. Comprehensive classification schemes for urothelial carcinoma have been proposed by three separate groups but have not previously been evaluated simultaneously in independent data. Here we map the interrelations between the proposed molecular subtypes onto the intrinsic structure of a rich independent dataset and show that subtype stratification within each scheme can be explained in terms of a set of common underlying biological processes. We highlight novel biological and genomic drivers of urothelial carcinoma molecular subtypes and show that tumors carrying genomic aberrations characteristic of distinct molecular pathways converge on a common top level phenotype corresponding to the two major molecular subtypes of non-muscle invasive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.